HPR10 Building Bridges Between Regulation, Health Technology Assessment and Clinical Guideline Development

Autor: M Hogervorst, M Mollebaek, RA Vreman, J Wang, AK Mantel-Teeuwisse, W Goettsch

Publikováno v: Value in Health. 25:S233-S234

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5a7a696b567b62697d2c3ec536747353
https://doi.org/10.1016/j.jval.2022.09.1142

HPR184 Uncertainties Around Tumour Agnostic Therapies in Europe: Barriers and Facilitators of Patient Access

Autor: M Hogervorst, W Goettsch, AK Mantel-Teeuwisse, L Bloem, RA Vreman

Publikováno v: Value in Health. 25:S266

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d97cbc7c8371741cbd5211a1222a5eb7
https://doi.org/10.1016/j.jval.2022.09.1313

OP18 Applicability of Appraisal Tools of Real-World Evidence in Health Technology Assessment: A Literature Review and Content Analysis

Autor: L Jiu, MK Hartog, J Wang, RA Vreman, AK Mantel-Teeuwisse, WG Goettsch

Publikováno v: Value in Health. 25:S389

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c02cfdfcee0a1474260bf1bc763e2a3e
https://doi.org/10.1016/j.jval.2022.09.1934

Stimulating development of innovative medicines in the European Union: does a new definition for unmet medical need add value?

Autor: Bloem LT; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands; Regulatory Science Network Netherlands, Utrecht, the Netherlands. Electronic address: l.t.bloem@uu.nl., Leufkens HGM; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands., Berends SE; Regulatory Science Network Netherlands, Utrecht, the Netherlands; Lygature, Utrecht, the Netherlands., Vreman RA; Roche Netherlands B.V, Woerden, the Netherlands., Hollak CEM; Department of Endocrinology and Metabolism, Amsterdam UMC, Amsterdam, the Netherlands., van Weely S; ZonMw, The Hague, the Netherlands., de Lannoy LM; Independent Patient Advocate, the Netherlands., Bertens PJA; Association Innovative Medicines, The Hague, the Netherlands., Pasmooij AMG; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands; Regulatory Science Network Netherlands, Utrecht, the Netherlands; Dutch Medicines Evaluation Board, Utrecht, the Netherlands. Electronic address: a.m.g.pasmooij@uu.nl.

Publikováno v: Drug discovery today [Drug Discov Today] 2024 Nov 26, pp. 104251. Date of Electronic Publication: 2024 Nov 26.

Illustrating the Financial Consequences of Outcome-Based Payment Models From a Payers Perspective: The Case of Autologous Gene Therapy Atidarsagene Autotemcel (Libmeldy®).

Autor: Callenbach MHE; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands., Schoenmakers D; Department of Child Neurology, Expertise Center Amsterdam Leukodystrophy Center, including lead of MLDi registry, Emma's Children's Hospital, Amsterdam UMC, Amsterdam, The Netherlands; Medicine for Society, Platform at Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands., Vreman RA; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands; National Health Care Institute (ZIN), Diemen, The Netherlands., Vijgen S; National Health Care Institute (ZIN), Diemen, The Netherlands., Timmers L; National Health Care Institute (ZIN), Diemen, The Netherlands., Hollak CEM; Medicine for Society, Platform at Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands; Department of Endocrinology and Metabolism, Expertise Center for Inborn Errors of Metabolism, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands., Mantel-Teeuwisse AK; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands., Goettsch WG; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands; National Health Care Institute (ZIN), Diemen, The Netherlands. Electronic address: w.g.goettsch@uu.nl.

Publikováno v: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research [Value Health] 2024 Aug; Vol. 27 (8), pp. 1046-1057. Date of Electronic Publication: 2024 May 23.